News briefing: Frequency posts extended positive results for hearing loss program; Kiniksa earns ODD for GCA candidate
Frequency Therapeutics presented results from a longer-term durability study of its acquired sensorineural hearing loss candidate, saying FX-322 showed significant improvement for some patients in key measures of hearing that were sustained for up to 21 months.
The data build upon Phase I/II results from 2019 where the program demonstrated statistically significant improvements in word recognition scores in patients with chronic SNHL, Frequency said. That study lasted for only 90 days, whereas Tuesday’s new data were part of subsequent testing of a subset of these patients between 13 and 21 months after initial dosing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.